Pretreatment assessment of prognostic indicators in endometrial cancer

Andrea Mariani, Thomas J. Sebo, Jerry A. Katzmann, Gary Keeney, Patrick C. Roche, Timothy G. Lesnick, Karl C. Podratz

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

OBJECTIVE: The object of this study was to assess the association of histologic, cytokinetic, and molecular variables in preoperative endometrial samples with extrauterine disease, recurrence, and survival among patients with endometrial cancer. STUDY DESIGN: In a case-cohort study of 125 women, ploidy, S-phase fraction, proliferative index, deoxyribonucleic acid index, proliferating cell nuclear antigen, MIB-1 proliferation marker, p53 tumor suppressor gene, and cytoplasmic HER-2/neu oncogene and bcl-2 expressions were quantitated. RESULTS: A model with only one independent term predicted progression-free survival; that variable was p53 (P < .0001; relative risk, 5.60). A model with two independent terms predicted disease-related survival; these variables were p53 (P = .0002; relative risk, 7.39) and MIB-1 (P = .03; relative risk, 3.27). Among patients with tumors with both p53 and MIB-1 expression exceeding 33%, a total of 32% had died of disease by 2 years. A model for predicting extrauterine disease selected two independent variables: p53 (odds ratio, 3.20; P = .01) and ploidy (odds ratio, 2.16; P = .04). An advanced surgical stage was encountered in 26% to 35% of cases in which either the p53 expression exceeded 33% or the deoxyribonucleic acid content was nondiploid and in 53% of cases in which both variables were unfavorable. CONCLUSIONS: Preoperative evaluation of quantifiable cytokinetic and molecular variables can assist in identifying tumor types that are predisposed toward a more aggressive clinical course.

Original languageEnglish (US)
Pages (from-to)1535-1544
Number of pages10
JournalAmerican Journal of Obstetrics and Gynecology
Volume182
Issue number6
DOIs
StatePublished - 2000

Fingerprint

Endometrial Neoplasms
Ploidies
Odds Ratio
Survival
DNA
Proliferating Cell Nuclear Antigen
Tumor Suppressor Genes
S Phase
Oncogenes
Disease-Free Survival
Neoplasms
Cohort Studies
Recurrence

Keywords

  • Bcl-2 Protein
  • Curettage
  • Cytokinetics
  • Endometrial carcinoma
  • HER-2/neu oncogene
  • MIB-1 (Ki-67)
  • p53 tumor suppressor gene
  • Ploidy
  • Prognosis
  • Proliferating cell nuclear antigen

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Mariani, A., Sebo, T. J., Katzmann, J. A., Keeney, G., Roche, P. C., Lesnick, T. G., & Podratz, K. C. (2000). Pretreatment assessment of prognostic indicators in endometrial cancer. American Journal of Obstetrics and Gynecology, 182(6), 1535-1544. https://doi.org/10.1067/mob.2000.107328

Pretreatment assessment of prognostic indicators in endometrial cancer. / Mariani, Andrea; Sebo, Thomas J.; Katzmann, Jerry A.; Keeney, Gary; Roche, Patrick C.; Lesnick, Timothy G.; Podratz, Karl C.

In: American Journal of Obstetrics and Gynecology, Vol. 182, No. 6, 2000, p. 1535-1544.

Research output: Contribution to journalArticle

Mariani, A, Sebo, TJ, Katzmann, JA, Keeney, G, Roche, PC, Lesnick, TG & Podratz, KC 2000, 'Pretreatment assessment of prognostic indicators in endometrial cancer', American Journal of Obstetrics and Gynecology, vol. 182, no. 6, pp. 1535-1544. https://doi.org/10.1067/mob.2000.107328
Mariani, Andrea ; Sebo, Thomas J. ; Katzmann, Jerry A. ; Keeney, Gary ; Roche, Patrick C. ; Lesnick, Timothy G. ; Podratz, Karl C. / Pretreatment assessment of prognostic indicators in endometrial cancer. In: American Journal of Obstetrics and Gynecology. 2000 ; Vol. 182, No. 6. pp. 1535-1544.
@article{2ec80135c0ad47548c4624b53b0a84f6,
title = "Pretreatment assessment of prognostic indicators in endometrial cancer",
abstract = "OBJECTIVE: The object of this study was to assess the association of histologic, cytokinetic, and molecular variables in preoperative endometrial samples with extrauterine disease, recurrence, and survival among patients with endometrial cancer. STUDY DESIGN: In a case-cohort study of 125 women, ploidy, S-phase fraction, proliferative index, deoxyribonucleic acid index, proliferating cell nuclear antigen, MIB-1 proliferation marker, p53 tumor suppressor gene, and cytoplasmic HER-2/neu oncogene and bcl-2 expressions were quantitated. RESULTS: A model with only one independent term predicted progression-free survival; that variable was p53 (P < .0001; relative risk, 5.60). A model with two independent terms predicted disease-related survival; these variables were p53 (P = .0002; relative risk, 7.39) and MIB-1 (P = .03; relative risk, 3.27). Among patients with tumors with both p53 and MIB-1 expression exceeding 33{\%}, a total of 32{\%} had died of disease by 2 years. A model for predicting extrauterine disease selected two independent variables: p53 (odds ratio, 3.20; P = .01) and ploidy (odds ratio, 2.16; P = .04). An advanced surgical stage was encountered in 26{\%} to 35{\%} of cases in which either the p53 expression exceeded 33{\%} or the deoxyribonucleic acid content was nondiploid and in 53{\%} of cases in which both variables were unfavorable. CONCLUSIONS: Preoperative evaluation of quantifiable cytokinetic and molecular variables can assist in identifying tumor types that are predisposed toward a more aggressive clinical course.",
keywords = "Bcl-2 Protein, Curettage, Cytokinetics, Endometrial carcinoma, HER-2/neu oncogene, MIB-1 (Ki-67), p53 tumor suppressor gene, Ploidy, Prognosis, Proliferating cell nuclear antigen",
author = "Andrea Mariani and Sebo, {Thomas J.} and Katzmann, {Jerry A.} and Gary Keeney and Roche, {Patrick C.} and Lesnick, {Timothy G.} and Podratz, {Karl C.}",
year = "2000",
doi = "10.1067/mob.2000.107328",
language = "English (US)",
volume = "182",
pages = "1535--1544",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Pretreatment assessment of prognostic indicators in endometrial cancer

AU - Mariani, Andrea

AU - Sebo, Thomas J.

AU - Katzmann, Jerry A.

AU - Keeney, Gary

AU - Roche, Patrick C.

AU - Lesnick, Timothy G.

AU - Podratz, Karl C.

PY - 2000

Y1 - 2000

N2 - OBJECTIVE: The object of this study was to assess the association of histologic, cytokinetic, and molecular variables in preoperative endometrial samples with extrauterine disease, recurrence, and survival among patients with endometrial cancer. STUDY DESIGN: In a case-cohort study of 125 women, ploidy, S-phase fraction, proliferative index, deoxyribonucleic acid index, proliferating cell nuclear antigen, MIB-1 proliferation marker, p53 tumor suppressor gene, and cytoplasmic HER-2/neu oncogene and bcl-2 expressions were quantitated. RESULTS: A model with only one independent term predicted progression-free survival; that variable was p53 (P < .0001; relative risk, 5.60). A model with two independent terms predicted disease-related survival; these variables were p53 (P = .0002; relative risk, 7.39) and MIB-1 (P = .03; relative risk, 3.27). Among patients with tumors with both p53 and MIB-1 expression exceeding 33%, a total of 32% had died of disease by 2 years. A model for predicting extrauterine disease selected two independent variables: p53 (odds ratio, 3.20; P = .01) and ploidy (odds ratio, 2.16; P = .04). An advanced surgical stage was encountered in 26% to 35% of cases in which either the p53 expression exceeded 33% or the deoxyribonucleic acid content was nondiploid and in 53% of cases in which both variables were unfavorable. CONCLUSIONS: Preoperative evaluation of quantifiable cytokinetic and molecular variables can assist in identifying tumor types that are predisposed toward a more aggressive clinical course.

AB - OBJECTIVE: The object of this study was to assess the association of histologic, cytokinetic, and molecular variables in preoperative endometrial samples with extrauterine disease, recurrence, and survival among patients with endometrial cancer. STUDY DESIGN: In a case-cohort study of 125 women, ploidy, S-phase fraction, proliferative index, deoxyribonucleic acid index, proliferating cell nuclear antigen, MIB-1 proliferation marker, p53 tumor suppressor gene, and cytoplasmic HER-2/neu oncogene and bcl-2 expressions were quantitated. RESULTS: A model with only one independent term predicted progression-free survival; that variable was p53 (P < .0001; relative risk, 5.60). A model with two independent terms predicted disease-related survival; these variables were p53 (P = .0002; relative risk, 7.39) and MIB-1 (P = .03; relative risk, 3.27). Among patients with tumors with both p53 and MIB-1 expression exceeding 33%, a total of 32% had died of disease by 2 years. A model for predicting extrauterine disease selected two independent variables: p53 (odds ratio, 3.20; P = .01) and ploidy (odds ratio, 2.16; P = .04). An advanced surgical stage was encountered in 26% to 35% of cases in which either the p53 expression exceeded 33% or the deoxyribonucleic acid content was nondiploid and in 53% of cases in which both variables were unfavorable. CONCLUSIONS: Preoperative evaluation of quantifiable cytokinetic and molecular variables can assist in identifying tumor types that are predisposed toward a more aggressive clinical course.

KW - Bcl-2 Protein

KW - Curettage

KW - Cytokinetics

KW - Endometrial carcinoma

KW - HER-2/neu oncogene

KW - MIB-1 (Ki-67)

KW - p53 tumor suppressor gene

KW - Ploidy

KW - Prognosis

KW - Proliferating cell nuclear antigen

UR - http://www.scopus.com/inward/record.url?scp=0033932042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033932042&partnerID=8YFLogxK

U2 - 10.1067/mob.2000.107328

DO - 10.1067/mob.2000.107328

M3 - Article

VL - 182

SP - 1535

EP - 1544

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -